Biological Activity
gdc-0941 is a novel selective class i phosphatidylinositol-3-kinase (pi3k) inhibitor. activation of pi3k/akt signaling pathway is frequently associated with tumorigenesis. deregulation of this pathway occurs frequently with a variety of cancers and may contribute to the resistance to many anticancer agents. [1] developing novel small molecules that specifically block the pi3k/akt pathway may inhibit tumor growth. gdc-0941 is designed to bind the atp-binding pocket of pi3k and to prevent formation of phosphatidylinositol-3, 4, 5-triphosphate (pip3), a second messenger that transmits pi3k downstream signals. [2, 3] it binds to pi3k in an atp-competitive manner.gdc-0941 is a potent small-molecule thieno [3, 2-d] pyrimidine inhibitor of the class i pi3k. it is highly selective against isoforms p110( and p110( with ic50 of 3 nm, and moderately selective against isoforms p110( and p110( with ic50s of 33 nm and 75 nm, respectively.gdc-0941 inhibits cell proliferation in vitro and in vivo. it causes growth inhibition in a variety of cancer cell lines, including a2780, mda-mb-361, pc3, and u87mg. [2] it also inhibits the growth of trastuzumab–sensitive and –resistant her2-amplied cancer cells which harbor p110( mutations or pten loss. [4] gdc-0941 also reduces tumor volume in different xenograft models. [4]gdc-0941 can be taken orally.
References
[1]yuan tl, cantley lc. pi3k pathway alterations in cancer: variations on a theme. oncogene. 2008;27:5497-5510.
[2]folkes aj, ahmadi k, alderton wk, et al. the identification of 2-(1h-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (gdc-0941) as a potent, selective, orally bioavailable inhibitor of class i pi3 kinase for the treatment of cancer. j med chem. 2008; 51: 5522-5532.
[3]knight za, shokat km. chemically targeting the pi3k family. biochem soc trans. 2007; 35: 245-249.
[4]junttila tt, akita rw, parsons k, fields c, lewis phillips gd, friedman ls, sampath d, sliwkowski mx. ligand-independent her2/her3/pi3k complex is disrupted by trastuzumab and is effectively inhibited by the pi3k inhibitor gdc-0941. br j cancer. 2011; 104(7): 1116-25.